Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akari Therapeutics PLC (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
AKTX
Nasdaq
8731
https://www.akaritx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akari Therapeutics PLC (ADR)
Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics
- May 1st, 2024 12:01 pm
Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity
- May 1st, 2024 12:00 pm
Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024
- Apr 15th, 2024 12:00 pm
Akari Therapeutics Insider Ups Holding By 69% During Year
- Apr 1st, 2024 5:13 pm
Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights
- Apr 1st, 2024 10:30 am
Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit
- Mar 5th, 2024 1:00 pm
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
- Jan 2nd, 2024 1:00 pm
Akari Therapeutics to Present at Biotech Showcase 2024
- Dec 14th, 2023 1:00 pm
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
- Dec 1st, 2023 1:00 pm
Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
- Nov 16th, 2023 1:00 pm
Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference
- Nov 6th, 2023 1:00 pm
Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now
- Oct 3rd, 2023 11:00 am
Akari Therapeutics Reports First Half 2023 Financial Results and Highlights
- Sep 29th, 2023 12:00 pm
Akari Therapeutics to Present at Emerging Growth Conference
- Sep 27th, 2023 12:00 pm
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit
- Sep 21st, 2023 12:00 pm
Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs
- Sep 19th, 2023 12:00 pm
Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Sep 5th, 2023 12:00 pm
Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials
- Aug 18th, 2023 12:00 pm
Akari Therapeutics, Plc Announces ADS Ratio Change
- Aug 15th, 2023 12:00 pm
Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs
- Aug 2nd, 2023 12:00 pm
Scroll